跳至主要内容
临床试验/NCT00367874
NCT00367874已完成4 期

Treatment of Polydrug-Using Opiate Dependents During Withdrawal

Sorlandet Hospital HF2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2003年2月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
12
试验地点
2
主要终点
Withdrawal symptoms

研究概览

简要总结

Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment.

In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common.

Objectives

  1. To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ).
  2. To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups.
  3. To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • - Polydrug dependency (at least opiate and benzodiazepine dependency)

排除标准

  • No severe psychiatric illness
  • No history of epilepsy seizures
  • No pregnancy or breastfeeding
  • Fertile women must use contraceptives

结局指标

主要结局

Withdrawal symptoms

Retention in treatment

次要结局

  • Serum concentration of Valproate and Buprenorphine separately and in combination
  • Urine testing

研究者

发起方
Sorlandet Hospital HF
申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验